Virtual reality support during systemic cancer therapy to improve anxiety/depressive symptoms and reduce toxicity in patients with gastrointestinal cancers—OncoVR
Background: Systemic cancer therapy may trigger anxiety/depressive symptoms and toxicity. Relaxation techniques can help alleviate toxicities but their implementation in clinical practice is challenging. We hypothesize that virtual reality (VR) systems which project a relaxing nature environment may...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-03-01
|
| Series: | ESMO Gastrointestinal Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2949819825000044 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832540401591910400 |
|---|---|
| author | S. Kasper S. Liszio K. Schorrmann M. Gerigk S. Jovic O. Basu K. Kostbade B. Goraus A. Elsakka B. Puladi J. Kleesiek M. Schuler G. Luijten J. Egger |
| author_facet | S. Kasper S. Liszio K. Schorrmann M. Gerigk S. Jovic O. Basu K. Kostbade B. Goraus A. Elsakka B. Puladi J. Kleesiek M. Schuler G. Luijten J. Egger |
| author_sort | S. Kasper |
| collection | DOAJ |
| description | Background: Systemic cancer therapy may trigger anxiety/depressive symptoms and toxicity. Relaxation techniques can help alleviate toxicities but their implementation in clinical practice is challenging. We hypothesize that virtual reality (VR) systems which project a relaxing nature environment may help to reduce psychological stress and toxicities of cancer therapies. This trial aims to evaluate the feasibility of a supportive VR intervention in patients receiving cancer therapies in an outpatient setting. Patients and methods: OncoVR is a randomized, open-label, cross-over trial to investigate the feasibility and impact of VR support during cancer therapy to improve anxiety, depressive symptoms, and toxicity in patients with gastrointestinal cancers. In total, 54 participants will be assigned to receive systemic therapy with VR support, followed by a subsequent course without VR support (arm A). Patients in arm B will first receive therapy without VR support, followed by a subsequent course with VR support. Primary endpoints are the feasibility of VR support (80% of the patients can tolerate its use for a minimum duration of 20 min), and changes in anxiety/depressive symptoms using the Hospital Anxiety and Depression Scale (HADS-D) and Positive and Negative Affect Schedule (PANAS) questionnaires. Secondary endpoints include the incidence and severity of therapy-associated toxicities per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) and Patient-Reported Outcomes version of the CTCAE (PRO-CTCAE) grading, and patient experience using the Player Experience Inventory (PXI) questionnaire. |
| format | Article |
| id | doaj-art-7e956335ea984268ab9cd58ba3c89e55 |
| institution | Kabale University |
| issn | 2949-8198 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | ESMO Gastrointestinal Oncology |
| spelling | doaj-art-7e956335ea984268ab9cd58ba3c89e552025-02-05T04:32:55ZengElsevierESMO Gastrointestinal Oncology2949-81982025-03-017100135Virtual reality support during systemic cancer therapy to improve anxiety/depressive symptoms and reduce toxicity in patients with gastrointestinal cancers—OncoVRS. Kasper0S. Liszio1K. Schorrmann2M. Gerigk3S. Jovic4O. Basu5K. Kostbade6B. Goraus7A. Elsakka8B. Puladi9J. Kleesiek10M. Schuler11G. Luijten12J. Egger13Department of Medical Oncology, West German Cancer, University Hospital Essen, Essen, Germany; National Center for Tumor Diseases (NCT) West, Essen, Germany; Correspondence to: Prof. Stefan Kasper, Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, NRW 45147, Germany. Tel: +492017233449The Center for Virtual and Extended Reality in Medicine, University Hospital Essen, Essen, GermanyInstitute for Artificial Intelligence in Medicine, University Hospital Essen, Essen, GermanyInstitute for Patient Experience, University Hospital Essen, Essen, GermanyInstitute for Patient Experience, University Hospital Essen, Essen, GermanyThe Center for Virtual and Extended Reality in Medicine, University Hospital Essen, Essen, GermanyDepartment of Medical Oncology, West German Cancer, University Hospital Essen, Essen, GermanyDepartment of Medical Oncology, West German Cancer, University Hospital Essen, Essen, GermanyInstitute for Artificial Intelligence in Medicine, University Hospital Essen, Essen, GermanyInstitute of Medical Informatics, University Hospital RWTH Aachen, Aachen, GermanyNational Center for Tumor Diseases (NCT) West, Essen, Germany; Institute for Artificial Intelligence in Medicine, University Hospital Essen, Essen, GermanyDepartment of Medical Oncology, West German Cancer, University Hospital Essen, Essen, Germany; National Center for Tumor Diseases (NCT) West, Essen, GermanyInstitute for Artificial Intelligence in Medicine, University Hospital Essen, Essen, GermanyNational Center for Tumor Diseases (NCT) West, Essen, Germany; Institute for Artificial Intelligence in Medicine, University Hospital Essen, Essen, GermanyBackground: Systemic cancer therapy may trigger anxiety/depressive symptoms and toxicity. Relaxation techniques can help alleviate toxicities but their implementation in clinical practice is challenging. We hypothesize that virtual reality (VR) systems which project a relaxing nature environment may help to reduce psychological stress and toxicities of cancer therapies. This trial aims to evaluate the feasibility of a supportive VR intervention in patients receiving cancer therapies in an outpatient setting. Patients and methods: OncoVR is a randomized, open-label, cross-over trial to investigate the feasibility and impact of VR support during cancer therapy to improve anxiety, depressive symptoms, and toxicity in patients with gastrointestinal cancers. In total, 54 participants will be assigned to receive systemic therapy with VR support, followed by a subsequent course without VR support (arm A). Patients in arm B will first receive therapy without VR support, followed by a subsequent course with VR support. Primary endpoints are the feasibility of VR support (80% of the patients can tolerate its use for a minimum duration of 20 min), and changes in anxiety/depressive symptoms using the Hospital Anxiety and Depression Scale (HADS-D) and Positive and Negative Affect Schedule (PANAS) questionnaires. Secondary endpoints include the incidence and severity of therapy-associated toxicities per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) and Patient-Reported Outcomes version of the CTCAE (PRO-CTCAE) grading, and patient experience using the Player Experience Inventory (PXI) questionnaire.http://www.sciencedirect.com/science/article/pii/S2949819825000044virtual realitycancer therapysupportive careclinical trialpatient experience |
| spellingShingle | S. Kasper S. Liszio K. Schorrmann M. Gerigk S. Jovic O. Basu K. Kostbade B. Goraus A. Elsakka B. Puladi J. Kleesiek M. Schuler G. Luijten J. Egger Virtual reality support during systemic cancer therapy to improve anxiety/depressive symptoms and reduce toxicity in patients with gastrointestinal cancers—OncoVR ESMO Gastrointestinal Oncology virtual reality cancer therapy supportive care clinical trial patient experience |
| title | Virtual reality support during systemic cancer therapy to improve anxiety/depressive symptoms and reduce toxicity in patients with gastrointestinal cancers—OncoVR |
| title_full | Virtual reality support during systemic cancer therapy to improve anxiety/depressive symptoms and reduce toxicity in patients with gastrointestinal cancers—OncoVR |
| title_fullStr | Virtual reality support during systemic cancer therapy to improve anxiety/depressive symptoms and reduce toxicity in patients with gastrointestinal cancers—OncoVR |
| title_full_unstemmed | Virtual reality support during systemic cancer therapy to improve anxiety/depressive symptoms and reduce toxicity in patients with gastrointestinal cancers—OncoVR |
| title_short | Virtual reality support during systemic cancer therapy to improve anxiety/depressive symptoms and reduce toxicity in patients with gastrointestinal cancers—OncoVR |
| title_sort | virtual reality support during systemic cancer therapy to improve anxiety depressive symptoms and reduce toxicity in patients with gastrointestinal cancers oncovr |
| topic | virtual reality cancer therapy supportive care clinical trial patient experience |
| url | http://www.sciencedirect.com/science/article/pii/S2949819825000044 |
| work_keys_str_mv | AT skasper virtualrealitysupportduringsystemiccancertherapytoimproveanxietydepressivesymptomsandreducetoxicityinpatientswithgastrointestinalcancersoncovr AT sliszio virtualrealitysupportduringsystemiccancertherapytoimproveanxietydepressivesymptomsandreducetoxicityinpatientswithgastrointestinalcancersoncovr AT kschorrmann virtualrealitysupportduringsystemiccancertherapytoimproveanxietydepressivesymptomsandreducetoxicityinpatientswithgastrointestinalcancersoncovr AT mgerigk virtualrealitysupportduringsystemiccancertherapytoimproveanxietydepressivesymptomsandreducetoxicityinpatientswithgastrointestinalcancersoncovr AT sjovic virtualrealitysupportduringsystemiccancertherapytoimproveanxietydepressivesymptomsandreducetoxicityinpatientswithgastrointestinalcancersoncovr AT obasu virtualrealitysupportduringsystemiccancertherapytoimproveanxietydepressivesymptomsandreducetoxicityinpatientswithgastrointestinalcancersoncovr AT kkostbade virtualrealitysupportduringsystemiccancertherapytoimproveanxietydepressivesymptomsandreducetoxicityinpatientswithgastrointestinalcancersoncovr AT bgoraus virtualrealitysupportduringsystemiccancertherapytoimproveanxietydepressivesymptomsandreducetoxicityinpatientswithgastrointestinalcancersoncovr AT aelsakka virtualrealitysupportduringsystemiccancertherapytoimproveanxietydepressivesymptomsandreducetoxicityinpatientswithgastrointestinalcancersoncovr AT bpuladi virtualrealitysupportduringsystemiccancertherapytoimproveanxietydepressivesymptomsandreducetoxicityinpatientswithgastrointestinalcancersoncovr AT jkleesiek virtualrealitysupportduringsystemiccancertherapytoimproveanxietydepressivesymptomsandreducetoxicityinpatientswithgastrointestinalcancersoncovr AT mschuler virtualrealitysupportduringsystemiccancertherapytoimproveanxietydepressivesymptomsandreducetoxicityinpatientswithgastrointestinalcancersoncovr AT gluijten virtualrealitysupportduringsystemiccancertherapytoimproveanxietydepressivesymptomsandreducetoxicityinpatientswithgastrointestinalcancersoncovr AT jegger virtualrealitysupportduringsystemiccancertherapytoimproveanxietydepressivesymptomsandreducetoxicityinpatientswithgastrointestinalcancersoncovr |